Island. Community outreach activities included radio ads, as well as distribution of patient handouts and wallet cards at community events.
Vaccination increased while pneumococcal disease decreased during the study period.
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Key Points
Background
• Pneumococcal vaccination remains well below the Healthy People 2020 goal of 90% in older adults, both nationally and in Rhode Island.
• Prior to the intervention, Rhode Island had a higher burden of invasive pneumococcal disease than the rates observed regionally or nationally.
• Pneumococcal vaccination recommendations have undergone several changes in recent years, including expanded indications for vaccination.
Findings
• Pharmacist-led academic detailing sessions improved self-reported immunization provider knowledge of PCV13 and PPVSV23 vaccination recommendations, resulting in intentions to apply this knowledge in clinical practice and expected changes in their vaccination practices.
Introduction
More than half of pneumococcal disease in older adults occurs in non-vaccinated patients who have an indication for pneumococcal vaccination. 1, 2 Moreover, an estimated 67 million at-risk individuals in the United States (US ) have not yet been vaccinated. 1, 2 This data is extremely concerning because patients with Advisory Committee on Immunization Practices (ACIP)
indications for pneumococcal vaccination are twice as likely to die as those without indications if they develop invasive pneumococcal disease. 3 Despite this grave reality, and efforts to improve national pneumococcal vaccination rates among populations that should be vaccinated, vaccinations rates rarely reach 75%. [4] [5] [6] Pneumococcal vaccination in adults aged 65 years and older has remained relatively stable over the past several years, however, it is still well below the Healthy People 2020 goal of 90%. 4 A significant challenge with adult vaccinations, as opposed to childhood vaccinations, is awareness of vaccination indications among immunization providers and patients. [7] [8] [9] [10] This is particularly problematic in adult populations since vaccine status assessment by healthcare providers is not routine, patients often receive care at multiple locations (indicating care may not be coordinated), and patients may be unaware of their immunization status. [7] [8] [9] [10] Further, pneumococcal vaccination recommendations have undergone several changes in recent years and can be complex depending on the patient's age, medical conditions, and previous pneumococcal vaccination status.
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Objectives
We developed a statewide pharmacist-led, education campaign utilizing academic detailing and patient outreach to improve adult pneumococcal rates by increasing knowledge and awareness of pneumococcal immunization recommendations. To assess the effectiveness of our approach for improving pneumococcal vaccination in Rhode Island through education, we evaluated a range of outcomes, including changes in vaccination rates, invasive pneumococcal infections, and pneumococcal pneumonia, as well as provider feedback on academic detailing.
Setting
Our education campaign targeted immunization providers and residents of Rhode Island.
Immunization providers were educated in the practice setting, as well as at conferences and meetings. Patients were educated at community events and through radio announcements.
Practice description
Decision pathway and educational materials Our target audience for the PSA was adults 65 years and older, and based on demographics provided by the advertising company, six radio stations were chosen. The PSA aired a total of 227 times in December 2014.
To reach patients of diverse backgrounds throughout Rhode Island, the study team and the URI Pharmacy Outreach Program attended over 100 public health events over the intervention period.
Events included public health fairs, such as the Feed 1,000 Rhode Islanders event for two consecutive years, brown bag events, support groups, and educational programs held at senior centers, senior housing, and community centers. Wallet cards, patient handouts, and sticks of lip 14 balm promoting pneumococcal vaccination were distributed to attendees. At several events, formal presentation about pneumococcal disease and pneumococcal vaccination were made to attendees.
Practice innovation
To our knowledge, this is the first statewide pharmacist-driven academic detailing and community outreach campaign to promote adult vaccination. Academic detailing is "university or noncommercial-based educational outreach which involves face-to-face education to prescribers by trained healthcare professionals". 16, 17 The goal of academic detailing is to provide education consistent with medical evidence and guidance documents. 16, 17 With the complexity of recommendations for pneumococcal vaccination, development of an easy-to-understand pathway and corresponding educational materials served as the backbone for our academic detailing efforts. Prior to pathway development, implementation of the ACIP recommendations was difficult due to a lack of public and provider knowledge, electronic medical record systems that did not automatically recommend the correct vaccine, and perceived and actual financial/reimbursement limitations, mainly from the primary payer for older adults, Medicare.
Evaluation
Immunization provider survey
After academic detailing sessions, each provider participant was requested to take an anonymous 15 followed a 5-point Likert scale, from strongly disagree = 1 to strongly agree = 5. We assessed the percent agreeing with each question (5 = strongly agree, 4 = agree). Health profession and setting were collected in the survey and question responses were compared between groups using the chi-square or Fisher's exact tests as appropriate.
Pneumococcal vaccination and infections
Vaccination
Pneumococcal vaccination was determined from the Behavioral Risk Factor Surveillance System (BRFSS), a national, cross-sectional survey which collects information about health behaviors, disease, and preventive services, such as vaccination. 6, 18 We evaluated the percentage of adult respondents 65 years and older who have ever had a pneumonia vaccination in Rhode Island and the US. Percent changes in the proportion of respondents answering "yes" to this question over the study period were assessed, as were absolute differences. Rhode Island BRFSS count data was obtained from the Rhode Island Department of Health, and US percentages were obtained from the Centers for Disease Control and Prevention BRFSS website.
Invasive pneumococcal disease, case reports
The goal of vaccination is to prevent morbidity and mortality, particularly invasive disease. As 
Pneumococcal disease, hospital discharge data
We assessed pneumococcal disease from hospital discharge data collected by the Rhode Island Department of Health. Discharge data is captured from 5 teaching hospitals providing general acute care, 6 other general acute-care hospitals, 2 psychiatric teaching hospitals, and 1 rehabilitation hospital. International Classification of Disease, 9 th revision (ICD-9) diagnosis codes were used to identify pneumococcal disease: pneumonia 481, bacteremia 038.2, and meningitis 320.1. Due to the switch from ICD-9 to ICD-10, hospital discharge data was only available through September 2015.
Statistical analysis
Discharge rates per 10,000 discharges and per 10,000 bed days were calculated. Invasive disease was calculated per 1,000,000 population. Using OpenEpi, changes in vaccination (for Rhode Island), infection type, inpatient mortality, and pneumococcal disease rate differences between the study periods were evaluated with chi-square, Fisher's exact, or t-tests, as appropriate. 22 
Ethics approval
This project was reviewed by the Institutional Review Board of the University of Rhode Island and was determined to be exempt according to federal regulations 45 CFR 46.101(b)(2) and 45 CFR 46.101(b)(4).
Results
Academic detailing
Academic detailing was assessed with surveys of licensed immunization providers. Overall, immunization providers found the academic detailing sessions to be effective with easy to understand materials (Tables 1 and 2 ). Most immunization providers agreed or strongly agreed (92%) that their knowledge of identifying which patient populations meet the recommendations for PCV13 or PPVSV23 improved. Providers intended to apply the knowledge in their clinical practice (83%), and expected their vaccination practices to change as a result of the academic detailing and education materials (73%). Almost 90% of immunization providers found the educational materials easy to understand. As compared with agreement in the community setting (Table 1) , there was significantly (p<0.05) less agreement with the questions in both the hospital setting (Q2-Q6) and the private practice setting (Q1, Q3-Q5). As compared with agreement reported by pharmacists ( 
Pneumococcal disease
After our pharmacist-led academic detailing program, annual rates of pneumococcal disease declined significantly by 2.8 per 10,000 discharges (Table 3 ; p=0.02). This resulted in 0.5 fewer bed days of care per 10,000 bed days (p=0.04). Rates of pneumococcal disease were largely driven by pneumococcal pneumonia over the entire study period (79.2%). Compared to the preintervention period, the proportion of pneumococcal disease discharges in Rhode Island with pneumococcal pneumonia decreased significantly in the intervention period (86.0% vs 75.5%; p=0.01), and the proportion with pneumococcal bacteremia increased (24.3% vs 33.6%; p=0.06).
Inpatient mortality was significantly lower in the intervention period compared to the preintervention period (8.8% vs 3.6%; p=0.03).
Before our academic detailing program began, the annual rate of invasive pneumococcal disease was higher in Rhode Island (72/1,000,000 persons) than in New England (47/1,000,000 persons)
or the United States (53/1,000,000 persons), as shown in 
Discussion
Since the implementation of our statewide academic detailing and community outreach intervention to increase pneumococcal vaccination among older adults, vaccination in the state increased significantly, and we observed other signals which infer increased vaccination, including a 5% decline in inpatient mortality among patient with pneumococcal disease.
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Additionally, we observed significant decreases in pneumococcal disease. Though the decline in invasive pneumococcal disease was at the boundary of statistical significance (p=0.05), Rhode
Island went from having nearly 20 more cases of invasive disease per year than the overall rate for the United States, to having a similar rate in the post-intervention period. Second, to account for seasonal changes in pneumococcal disease, the study periods were divided by calendar year, so the intervention period included a 5 month wash-out period without active academic detailing or community outreach activities. Though academic detailing began in
November 2013, few sessions were conducted due to the holidays. As immediate effects on statewide pneumococcal disease rates from these sessions were not expected, categorization by calendar year was considered appropriate. Additionally, due to the switch from International Classification of Diseases 9 th Edition to 10 th Edition in October 2015, the codes for pneumococcal disease changed, and pneumococcal hospital discharges from the last quarter of 2015 onward
were not included as rate differences may have been artefactual. Therefore, the intervention period for pneumococcal hospital discharges ended in September 2015. Third, though community pharmacies received two academic detailing sessions, different pharmacists may have participated in the detailing sessions, and as such, we were not able to follow-up with immunization providers to determine use of the academic detailing material in the practice or whether the pathways changed their immunization practices. Fourth, we could not calculate a response rate for the academic detailing survey. These results may be limited by response bias,
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since the exact number of attendees was not known for some academic detailing sessions, and some pharmacists may have received academic detailing on multiple occasions. Fifth, we attempted to collect vaccination data from several sources, other than BRFSS, however, we were not able to obtain these data. Lastly, we were not able to control for other factors that may have influenced vaccination practices over time, including vaccine advertisements or internal immunization provider policies to increase pneumococcal vaccination.
Conclusions
Our statewide pharmacist-driven campaign to increase adult pneumococcal vaccination through academic detailing to immunization providers and community outreach efforts resulted in increased self-reported provider knowledge regarding the pneumococcal vaccine. During the study period, we observed increases in vaccination and decreases in pneumococcal disease in Rhode Island. 2. The educational material is easy to understand.
3. This academic detailing session was effective.
4. As a result of this education, I am confident that I can apply this knowledge in clinical practice.
5. As a result of this education, I intend to apply the vaccination pathway in my practice.
6. As a result of this education, I expect my vaccination practices to change.
Comments for specific questions.
Please use the space below to add overall comments about the academic detailing or educational materials. 
Pneumococcal Vaccination Naive or Unknown History
Previously vaccinated with one dose PPSV23
Pneumococcal Vaccination Naive or Unknown History
At Age ≥65 OR who SMOKE or live in a NURSING HOME * Minimum interval between sequential administration of PCV13 and PPSV23 is 8 weeks in immunocompromised patients.
For Medicare reimbursement interval must be 11 full months. Please refer to page 4. † The ACIP (Advisory Committee on Immunization Practices) recommends only 1 dose of PPSV23 at age ≥65. Revaccination is not necessary. § A second PPSV23 for patients with cerebrospinal fluid leak, or cochlear implant is not required. 
PPSV23=23-Valent
Pneumococcal Polysaccharide Vaccine (Pneumovax ® 23) PCV13=13-Valent Pneumococcal Conjugate Vaccine (Prevnar 13 ® ) R H O D E I S L A N D D E P A R T M E N T O
